Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: A randomized, controlled trial

Peter C. Taylor, Didier Saurigny, Jiri Vencovsky, Tsutomu Takeuchi, Tadashi Nakamura, Galina Matsievskaia, Barbara Hunt, Thomas Wagner, Bernard Souberbielle

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: A randomized, controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences